Merck KGaA’s MilliporeSigma and Baylor College of Medicine joined together to work on vaccines against neglected diseases.

Meissa Vaccines, a JLABS resident startup, has financial backing from the NIH and a VC firm to help advance its RSV vaccine candidate.

Valneva and Emergent BioSolutions will co-develop a Zika candidate slated to enter phase 1 in late 2017 or early 2018.

For three of the world’s top four vaccine companies, sales growth churned along in the second quarter as other areas struggled.

J&J's Janssen unit will shell out up to $879 million to develop HIV and HBV vaccines using Bavarian Nordic's MVA-BN technology.

On the heels of new genital herpes data, one analyst believes things may get a whole lot better at Genocea.

Novavax's shares slid 19% after topline data from a new phase 2 trial on its RSV vaccine fail to impress investors.

BiodVax will test its universal flu vaccine candidate M-001 as a standalone shot after it elicited positive immune responses as a primer in a phase 2b trial.

Infectious Diseases